Recent Updates
Recently added Catalysts

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

Phase 2

COVID-19 Infection | Monoclonal antibody | Infectious Disease |GeoVax Labs, Inc.|Last Updated: Feb 9, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment119
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04639466A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 InfectionPHASE1/PHASE2 COMPLETED 119 — — Nov 1, 2020Dec 1, 2025Feb 9, 2026 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Placebo AdministrationDRUGGiven IM in the non-dominant upper arm
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1BIOLOGICALGiven IM in the non-dominant upper arm
Unlock Study Design Details